Fig 1.
Diagram of the study design showing the 3 experimental phases: housing and acclimation phase, experimental phases 1 and 2.
DXM, dexamethasone; D, day.
Fig 2.
Clinical scores (mean ±SD) for the MOX- or IVM-treated and control pigs over time, from scabies-infection induction throughout the post-treatment period.
Clinical scores are based on the scabies lesion-involved skin area (scored 0–6: 0, 0%; 1, <10%; 2, 10–29%; 3, 30–49%; 4, 50–69%; 5, 70–89%; 6, 90–100%), skin erythema (scored 0–4: 0, no erythema; 1, mild; 2, moderate; 3, severe; 4, extremely severe) and crusting intensity (scored 2× 0–4: 0, no crust; 1, grey to white, thin and irregular 1–2 mm crust; 2, 2–5 mm crust; 3, grey-brown >5 mm crust; and 4, >5 mm, hard crust). The score was calculated for 5 different anatomic sites and added. W, week; D, day.
Fig 3.
Pruritus scores (mean ±SD) over time from scabies-infection induction throughout the post-treatment period for MOX- and IVM-treated groups and control pigs.
W, week; D, day.
Fig 4.
ELISA-assessed serological responses (expressed as mean %OD ± SD) after S. scabiei infection throughout the post-treatment period of the MOX- and IVM-treated groups and control pigs.
W, week; D, day.
Table 1.
Primary outcome of MOX, IVM or no treatment of experimental scabies in pigs.
Table 2.
MOX and IVM pharmacokinetic parameters of scabies-infected pig plasma and skin.
Fig 5.
Plasma MOX and IVM concentrations (mean ± SD, ng/ml) after oral intake in scabies-infected pigs.
Concentrations measured on hour 1, 6 and 24 of D0 for MOX and hour 6 and 24 of D0 for IVM and on D2, 5, 7, 9, 12, 14, 22, 28, 36, 43, and 47 post-treatment are depicted. W, week; D, day.
Fig 6.
Skin MOX and IVM concentrations (mean ± SD, ng/g) after oral intake in scabies-infected pigs.
Concentrations measured on D2, 7, 9, 14, 22, 36, and 47 post-treatment are depicted. Predicted parts of the curves are indicated as a dashed line. W, week; D, day.